# InnoVec Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovec-biotherapeutics

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: https://www.innovecbio.com/
- Latest round: Series A (Jun 12, 2025)
- Investors on record: 2

## About

Established in 2020 and based in Beijing, China, InnoVec Biotherapeutics focuses on the advancement of innovative medical technologies. In June 2025, InnoVec Biotherapeutics raised an undisclosed amount of series A+ funding led by returning investor Tianjin Venture Capital, with participation from other undisclosed investors. InnoVec Biotherapeutics specializes in the development and commercialization of innovative medical devices aimed at enhancing patient care and outcomes. The company’s core offerings include advanced diagnostic tools and therapeutic devices that address various healthcare challenges, particularly in chronic disease management and early disease detection. These products support healthcare professionals in delivering effective treatments and improving patient monitoring capabilities. It serves client base including hospitals, outpatient clinics, and healthcare providers primarily in Asia and Europe. It generates revenue through a multifaceted business model that includes direct-to-consumer sales and partnerships with healthcare institutions. Transactions typically involve the sale of proprietary medical devices, priced based on their complexity and technology. Flagship products generally follow a one-time purchase model, while specific diagnostics operate on a subscription basis for ongoing support and updates. The revenue structure also encompasses arrangements with distributors and wholesalers who facilitate the broader market reach of its offerings. InnoVec Biotherapeutics plans to launch new products designed for chronic disease management and expects to release these innovations by mid-2026. The company targets expansion into the Southeast Asian and European markets by the end of 2026. The company will use the series A+ funding for clinical validation and advancement of the product pipeline and innovation of gene delivery platforms.

## Funding rounds

- Series A, Jun 12, 2025 — Tianjin Venture Capital
- Series A, May 15, 2025 — Tianjin Venture Capital
- Angel, Jun 1, 2021 — China Growth Capital

## Investors

- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Angel
- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Series A